FluidForm Bio

FluidForm Bio develops FRESH 3D bioprinting technology to create implantable, vascularized tissue constructs that support the long-term survival and function of therapeutic cells. The approach yields minimally invasive, easily retrievable implants with dense vascularization just under the skin, forming a platform for complex tissue engineering. By combining synthetic biology, 3D printing, advanced materials, and AI, FRESH provides a platform to engineer tissues that thrive in the body.

AI named FluidForm Bio from January 2026 to August 2026.